This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Inozyme Pharma (INZY) Hisse Özeti

INZY temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	0/6

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Son 3 ayda hisse senedi fiyatı US piyasasına kıyasla oldukça dalgalı

1 yıldan az nakit akışı var

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 12.3% oranında düşmesi öngörülüyor

+ 1 daha fazla risk

INZY Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Inozyme Pharma, Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Inozyme Pharma
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$4.00
52 Haftanın En Yüksek Seviyesi	US$6.24
52 Haftanın En Düşük Seviyesi	US$0.72
Beta	2.29
1 Aylık Değişim	0.50%
3 Aylık Değişim	387.09%
1 Yıllık Değişim	-10.91%
3 Yıllık Değişim	-21.26%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-77.20%

Son Haberler & Güncellemeler

Recent updates

Analiz Makalesi • Nov 17

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Analiz Makalesi • Aug 03

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Seeking Alpha • Jul 30

Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion

Summary Inozyme Pharma, Inc. interim data from the phase 1 SEAPORT-1 study, using INZ-701 for the treatment of patients with end-stage kidney disease with hemodialysis with calciphylaxis, expected Q4 of 2024. Fast Track Designation given by the FDA for the use of INZ-701 for the treatment of patients with ABCC6 Deficiency. Meeting with FDA to discuss potential of initiating a pivotal late-stage study using INZ-701 for the treatment of pediatric patients with ABCC6 Deficiency, expected end of 2024. Company had $166.2 million in cash as of March 31st of 2024; Enough cash on hand to fund its operations into Q4 of 2025. Read the full article on Seeking Alpha

Analiz Makalesi • Apr 11

Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Seeking Alpha • Mar 08

Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward

Summary 48-week results from the phase 1/2 studies, using INZ-701 for the treatment of patients with ENPP1 Deficiency and ABCC6 Deficiency, expected in Q1 2024. Results from the phase 3 ENERGY-3 study, using INZ-701 for the treatment of patients with ENPP1 Deficiency, expected in mid-2025. An expansion opportunity exists for this company, which would be the advancement of INZ-701 for calciphylaxis that occurs in patients with end-stage kidney disease receiving hemodialysis. Initiation of phase 1 SEAPORT-1 study, using INZ-701 for calciphylaxis that occurs in patients with end-stage kidney disease receiving hemodialysis expected in 1st half 2024; Interim data Q4 of 2024. Read the full article on Seeking Alpha

Seeking Alpha • Aug 15

Inozyme Pharma GAAP EPS of -$0.38

Inozyme Pharma press release (NASDAQ:INZY): Q2 GAAP EPS of -$0.38. Cash, cash equivalents, and investments were $151.5M as of June 30, 2022. Based on its current plans, the company expects that its cash, cash equivalents, and investments as of June 30, 2022, together with the $25M available under the first tranche of its debt facility, will enable the company to fund its cash flow requirements into the second quarter of 2024.

Seeking Alpha • Jul 19

Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency

Data from a handful of patients in the phase 1 portion of a phase 1/2 trial showed that Inozyme Pharma's (NASDAQ:INZY) INZ-701 led to positive biomarker, safety, and pharmacokinetic results in adults with ABCC6 Deficiency. All three adults showed rapid and significant increases in levels of pyrophosphate (PPi), a calcification inhibitor, after receiving the drug at a dose of 0.2 mg/kg. The company said in preclinical studies, PPi was predictive biomarker of therapeutic benefit. There were no serious adverse events reported. A grade 1 event was reported, though it was not related to INZ-701. Following review by a data safety monitoring board, InoZyme (INZY) plans to begin dosing in the next 0.6 mg/kg cohort this quarter and report topline data from Phase 1/2 trial in Q1 2023. Read about Inozyme's (INZY) recent partnership with the Rady Children’s Institute for Genomic Medicine.

Analiz Makalesi • Jul 12

Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Analiz Makalesi • Apr 06

We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Analiz Makalesi • Dec 22

Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Sep 08

Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • May 22

We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Feb 06

We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Hissedar Getirileri

	INZY	US Biotechs	US Pazar
7D	0%	1.2%	1.0%
1Y	-10.9%	34.9%	28.7%

Getiri vs. Endüstri: INZY geçen yıl boyunca % 34.9 oranında getiri sağlayan US Biotechs sektörüyle eşleşti.

Getiri vs Piyasa: INZY geçen yıl % 28.7 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is INZY's price volatile compared to industry and market?
INZY volatility
INZY Average Weekly Movement	53.9%
Biotechs Industry Average Movement	11.0%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.4%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: INZY hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.

Zaman İçindeki Volatilite: INZY 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 28% dan 54% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2015	67	Doug Treco	www.inozyme.com

Klinik aşamada bir biyofarmasötik şirketi olan Inozyme Pharma, Inc. kemik sağlığını ve kan damarı işlevini etkileyen nadir hastalıklar için terapötikler geliştirmektedir. Şirketin öncü ürün adayı, ENPP1 ve ABCC6 eksikliklerinin ve kalsifilaksinin yanı sıra hemodiyaliz alan son dönem böbrek hastalığı olan hastaların tedavisi için çözünür, rekombinant, genetik olarak tasarlanmış ve ENPP1 füzyon proteini olan INZ-701'den oluşmaktadır. Ayrıca posterior longitudinal ligament (OPLL) kemikleşmesinin tedavisi için Next Gen ERT ve PPi-Adenosine Pathway hastalığı olan Gen terapisi geliştirmektedir.

Inozyme Pharma, Inc. Temel Bilgiler Özeti

Inozyme Pharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
INZY temel i̇stati̇sti̇kler
Piyasa değeri	US$259.66m
Kazançlar(TTM)	-US$106.72m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-2.4x

F/K Oranı

INZY aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
INZY gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$106.72m
Kazançlar	-US$106.72m

Son Raporlanan Kazançlar

Mar 31, 2025

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.64
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	145.6%

INZY uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/07/03 22:04
Gün Sonu Hisse Fiyatı	2025/06/30 00:00
Kazançlar	2025/03/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Inozyme Pharma, Inc. 4 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Edward White	H.C. Wainwright & Co.
Joseph Stringer	Needham & Company
Dae Gon Ha	Stifel, Equities Research

This company has been acquired

Inozyme Pharma (INZY) Hisse Özeti

Risk Analizi

Inozyme Pharma, Inc. Rakipler

COMPASS Pathways

Tonix Pharmaceuticals Holding

Allogene Therapeutics

Annexon

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

New major risk - Revenue and earnings growth

Inozyme Pharma, Inc.(NasdaqGS:INZY) dropped from NASDAQ Composite Index

Price target decreased by 70% to US$4.00

Insufficient new directors

BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN) agreed to acquire Inozyme Pharma, Inc. (NasdaqGS:INZY) for approximately $260 million.

Inozyme Pharma, Inc., Annual General Meeting, Jun 25, 2025

Recent updates

New major risk - Revenue and earnings growth

Inozyme Pharma, Inc.(NasdaqGS:INZY) dropped from NASDAQ Composite Index

Price target decreased by 70% to US$4.00

Insufficient new directors

BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN) agreed to acquire Inozyme Pharma, Inc. (NasdaqGS:INZY) for approximately $260 million.

Inozyme Pharma, Inc., Annual General Meeting, Jun 25, 2025

Inozyme Pharma, Inc. Auditor Raises 'Going Concern' Doubt

Inozyme Pharma, Inc. Announces Workforce Reduction of Approximately 25% of Employees Implemented in the First Quarter of 2025

New minor risk - Market cap size

Price target decreased by 8.0% to US$18.00

New minor risk - Share price stability

Inozyme Pharma, Inc. Announces Positive Interim Data for Inz-701 in Infants and Young Children with Enpp1 Deficiency and Key Program Updates

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Inozyme Pharma, Inc. Announces Positive Interim Data from Phase 1 Seaport 1 Trial of INZ-701

Inozyme Pharma, Inc. Announces Appointment of Erik Harris to its Board of Directors

New major risk - Financial position

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion

Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency

New major risk - Revenue and earnings growth

Price target decreased by 7.5% to US$19.43

New major risk - Revenue and earnings growth

Inozyme Pharma, Inc., Annual General Meeting, Jun 18, 2024

Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?

Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency (PXE) and ENPP1 Deficiency

CEO & Chairman exercised options and sold US$52k worth of stock

New minor risk - Share price stability

Inozyme Pharma, Inc. to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency

New major risk - Revenue and earnings growth

Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward

Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy in Genomics England's Generation Study of Rare Conditions

Inozyme Pharma, Inc. Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

New minor risk - Share price stability

Price target decreased by 9.3% to US$20.50

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Inozyme Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $60 million.

Price target increased by 8.5% to US$22.60

Inozyme Pharma, Inc. Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency

Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in Phase 1b Trial of INZ-701

Insufficient new directors

Price target decreased by 13% to US$19.17

Inozyme Pharma, Inc. Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701

Price target increased by 8.5% to US$21.80

Inozyme Pharma, Inc. Provides Business Updates

Inozyme Pharma, Inc. Announces First Self-Administration of Inz-701 in Ongoing Enpp1 Deficiency Phase 1/2 Clinical Trial

Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database

Price target increased to US$23.20

Inozyme Pharma GAAP EPS of -$0.38

Inozyme Pharma, Inc. Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency

Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

Inozyme Pharma, Inc.(NasdaqGS:INZY) dropped from Russell 2500 Index

Inozyme Pharma, Inc. Appoints Kurt Gunter as Chief Medical Officer

Price target decreased to US$29.40

Inozyme Pharma, Inc. Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency

We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Inozyme Pharma, Inc. Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency

Price target decreased to US$30.00

Inozyme Pharma, Inc. Announces Management Changes

High number of new directors